Make sure to sign up for an account today for exclusive coupons and free shipping on orders over $75!
Maximum quantity allowed is 999
CAS RN: 61825-94-3 | Product Number: O0372
Oxaliplatin
Purity:
- (trans-1,2-Cyclohexanediamine)oxalatoplatinum(II)
Size | Unit Price | Philadelphia, PA | Portland, OR | Japan* | Quantity |
---|---|---|---|---|---|
100MG |
$208.00
|
1 | 3 | ≥100 |
|
* Items in stock locally ship in 1-2 business days. Items from Japan stock are able to ship from a US warehouse within 2 weeks. Please contact TCI for lead times on items not in stock. Excludes regulated items and items that ship on ice.
* To send your quote request for bulk quantities, please click on the "Request Quote" button. Please note that we cannot offer bulk quantities for some products.
*TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.
Product Number | O0372 |
Molecular Formula / Molecular Weight | C__8H__1__4N__2O__4Pt = 397.29 |
Physical State (20 deg.C) | Solid |
Storage Temperature | Refrigerated (0-10°C) |
Store Under Inert Gas | Store under inert gas |
Condition to Avoid | Moisture Sensitive,Heat Sensitive |
Packaging and Container | 100MG-Glass Bottle with Plastic Insert (View image) |
CAS RN | 61825-94-3 |
Reaxys Registry Number | 14621501 |
PubChem Substance ID | 125309438 |
Merck Index (14) | 6912 |
MDL Number | MFCD00866327 |
Appearance | White to Almost white powder to crystal |
Elemental analysis(Nitrogen) | 6.70 to 7.40 % |
NMR | confirm to structure |
Pictogram | |
Signal Word | Danger |
Hazard Statements | H315 : Causes skin irritation. H319 : Causes serious eye irritation. H317 : May cause an allergic skin reaction. H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled. H341 : Suspected of causing genetic defects. |
Precautionary Statements | P501 : Dispose of contents/ container to an approved waste disposal plant. P261 : Avoid breathing dust/ fume/ gas/ mist/ vapors/ spray. P202 : Do not handle until all safety precautions have been read and understood. P285 : In case of inadequate ventilation wear respiratory protection. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection. P272 : Contaminated work clothing must not be allowed out of the workplace. P308 + P313 : IF exposed or concerned: Get medical advice/ attention. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P304 + P341 : IF INHALED: If breathing is difficult, remove person to fresh air and keep comfortable for breathing. P302 + P352 : IF ON SKIN: Wash with plenty of soap and water. P333 + P313 : If skin irritation or rash occurs: Get medical advice/ attention. P362 : Take off contaminated clothing and wash before reuse. P405 : Store locked up. |
RTECS# | TP2275850 |
HS Number | 2931.90.9052 |
The platinum complexes diffuse to the tumor cell, where they undergo hydrolysis displacement of their one chloride or carboxylate group leading to a platinum cation. The resulting cation coordinates to the guanine N7-position of DNA give a coordination cation. Then, intrastrand cross-linking occurs to anther guanine via further hydrolysis displacement of the remaining chloride or carboxylate. The forming [Pt(NH2R)2]2+ ― DNA complex distort the DNA helix (Fig. 1 and 2)6). Thus, DNA duplication is hindered, which ultimately triggers tumor cell apoptosis.3)
References
- 1)G. Mathe, Y. Kidani, M. Segiguchi, M. Eriguchi, G. Fredj, G. Peytavin, J. L. Misset, S. Brienza, F. de Vassals, E. Chenu, C. Bourut, Biomed. Pharmacother. 1989, 43, 237.
- 2)L. R. Kelland, S. Y. Sharp, C. F. O’Neill, F. I. Raynaud, P. J. Beale, I. R. Judson, J. Inorg. Biochem. 1999, 77, 111.
- 3)D. Wang, S. J. Lippard, Nat. Rev. Drug Discov. 2005, 4, 307.
- 4)S. Trzaska, Chem. Eng. News 2005, 83, 3.
- 5)L. P. Martin, T. C. Hamilton, R. J. Schilder, Clin. Cancer Res. 2008, 14, 1291.
- 6)A. Gelasco, S. J. Lippard, Biochemistry, 1998, 37, 9230.
References
- Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat
- Behavioral and immunohistological assessment of painful neuropathy induced by a single oxaliplatin injection in the rat
- Mexiletine reverses oxaliplatin-induced neuropathic pain in rats
- N. Egashira, S. Hirakawa, T. Kawashiri, T. Yano, H. Ikesue, R. Oishi, J. Pharmacol. Sci. 2010, 112, 473.
References
- Cellular and molecular pharmacology of oxaliplatin
- E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, E. Cvitkovic, Mol. Cancer Therapeutics 2002, 1, 227.
- Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA
- J. M. Woynarowski, W. G. Chapman, C. Napier, M. C. S. Herzig, P. Juniewicz, Mol. Pharmacol. 1998, 54, 770.
- Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum
Articles/Brochures
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
Specifications
C of A & Other Certificates
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.